Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19)

Author(s): Habeb Al-Kamel*, Oliver Grundmann

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 21 , Issue 16 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

COVID-19 is an emerging viral infection of zoonotic origin that is closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused an outbreak in 2003. Therefore, scientists named the new virus SARS-CoV-2. On March 11, 2020, The World Health Organization (WHO) recognized COVID-19 as a global pandemic. At present, three vaccines have been approved or are being considered for approval by national regulatory agencies to immunize against COVID- 19. However, the vaccines do not remain widely available, and no specific treatment against the virus is available. The pathogenesis and proliferation pathways of SARS-CoV-2 are still not well known. Thus, in this article, the saponin glycyrrhizin is discussed as a new potential therapeutic agent of natural origin (licorice root, Glycyrrhiza glabra) for the potential treatment of COVID-19 infections.

Keywords: Coronavirus, SARS-COV-2, COVID-19, glycyrrhizin, broad-spectrum antiviral agent, licorice Root.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 16
Year: 2021
Published on: 10 February, 2021
Page: [2204 - 2208]
Pages: 5
DOI: 10.2174/1389557521666210210160237
Price: $65

Article Metrics

PDF: 117